ALBI分级使出血事件的风险分层和阿特唑单抗和贝伐单抗后晚期HCC的预后预测更加精确。

IF 4.2 3区 医学 Q2 ONCOLOGY
Journal of Hepatocellular Carcinoma Pub Date : 2025-04-04 eCollection Date: 2025-01-01 DOI:10.2147/JHC.S462701
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Naoshi Nishida, Celina Ang, Thomas U Marron, Y Linda Wu, Anwaar Saeed, Brooke Wietharn, Lorenza Rimassa, Angelo Pirozzi, Antonella Cammarota, Tiziana Pressiani, Matthias Pinter, Lorenz Balcar, Yi-Hsiang Huang, Aman Mehan, Samuel Phen, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Adel Samson, Peter R Galle, Masatoshi Kudo, Giulia Francesca Manfredi, Ciro Celsa, Nichola Awosika, Alessio Cortellini, Amit G Singal, Rohini Sharma, Hong Jae Chon, Francesco Tovoli, Fabio Piscaglia, David James Pinato, Antonio D'Alessio
{"title":"ALBI分级使出血事件的风险分层和阿特唑单抗和贝伐单抗后晚期HCC的预后预测更加精确。","authors":"Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Naoshi Nishida, Celina Ang, Thomas U Marron, Y Linda Wu, Anwaar Saeed, Brooke Wietharn, Lorenza Rimassa, Angelo Pirozzi, Antonella Cammarota, Tiziana Pressiani, Matthias Pinter, Lorenz Balcar, Yi-Hsiang Huang, Aman Mehan, Samuel Phen, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Adel Samson, Peter R Galle, Masatoshi Kudo, Giulia Francesca Manfredi, Ciro Celsa, Nichola Awosika, Alessio Cortellini, Amit G Singal, Rohini Sharma, Hong Jae Chon, Francesco Tovoli, Fabio Piscaglia, David James Pinato, Antonio D'Alessio","doi":"10.2147/JHC.S462701","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Atezolizumab and bevacizumab (A+B) are recommended for treating unresectable hepatocellular carcinoma (HCC). Although highly effective, A+B can lead to potentially life-threatening adverse events including bleeding. We investigated whether albumin-bilirubin (ALBI) grade identifies patients with a higher risk of bleeding and its impact on prognosis than the Child-Pugh (CP) score.</p><p><strong>Methods: </strong>We performed a multicenter retrospective study of 15 tertiary referral centers that consecutively treated patients with A+B. We analyzed the association between the ALBI grade and gastrointestinal bleeding using the χ2 test. Overall survival (OS) stratified by ALBI was estimated using the Kaplan-Meier method and the predictive value for the 6-months OS landmark with ROC curves.</p><p><strong>Results: </strong>Of the 368 patients included in the analysis, 163 (44.3%), 192 (52.2%) and 13 (3.5%) had ALBI 1, ALBI 2, and ALBI 3, respectively. ALBI grade was associated with a 3-fold increase in bleeding risk (3.1% in ALBI 1 vs 10.2% in ALBI 2/3, p=0.008). Among 192 patients with pre-treatment EGD, G2 and G3 varices were associated with an increased risk of bleeding, whereas G1 varices had a similar risk as no varices. Patients with ALBI 1 achieved a longer median OS (not reached; 95% CI, 24.9-33.7), than ALBI 2 (9.7 months; 95% CI, 7.0-12.3) or ALBI 3 (5.6 months; 95% CI, 0.1-12.0). ALBI outperformed the CP score for predicting 6-month OS with an AUC 0.79 of ALBI versus 0.71 for the CP score (p=0.01).</p><p><strong>Conclusion: </strong>A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"671-683"},"PeriodicalIF":4.2000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977629/pdf/","citationCount":"0","resultStr":"{\"title\":\"ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.\",\"authors\":\"Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, Naoshi Nishida, Celina Ang, Thomas U Marron, Y Linda Wu, Anwaar Saeed, Brooke Wietharn, Lorenza Rimassa, Angelo Pirozzi, Antonella Cammarota, Tiziana Pressiani, Matthias Pinter, Lorenz Balcar, Yi-Hsiang Huang, Aman Mehan, Samuel Phen, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Adel Samson, Peter R Galle, Masatoshi Kudo, Giulia Francesca Manfredi, Ciro Celsa, Nichola Awosika, Alessio Cortellini, Amit G Singal, Rohini Sharma, Hong Jae Chon, Francesco Tovoli, Fabio Piscaglia, David James Pinato, Antonio D'Alessio\",\"doi\":\"10.2147/JHC.S462701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Atezolizumab and bevacizumab (A+B) are recommended for treating unresectable hepatocellular carcinoma (HCC). Although highly effective, A+B can lead to potentially life-threatening adverse events including bleeding. We investigated whether albumin-bilirubin (ALBI) grade identifies patients with a higher risk of bleeding and its impact on prognosis than the Child-Pugh (CP) score.</p><p><strong>Methods: </strong>We performed a multicenter retrospective study of 15 tertiary referral centers that consecutively treated patients with A+B. We analyzed the association between the ALBI grade and gastrointestinal bleeding using the χ2 test. Overall survival (OS) stratified by ALBI was estimated using the Kaplan-Meier method and the predictive value for the 6-months OS landmark with ROC curves.</p><p><strong>Results: </strong>Of the 368 patients included in the analysis, 163 (44.3%), 192 (52.2%) and 13 (3.5%) had ALBI 1, ALBI 2, and ALBI 3, respectively. ALBI grade was associated with a 3-fold increase in bleeding risk (3.1% in ALBI 1 vs 10.2% in ALBI 2/3, p=0.008). Among 192 patients with pre-treatment EGD, G2 and G3 varices were associated with an increased risk of bleeding, whereas G1 varices had a similar risk as no varices. Patients with ALBI 1 achieved a longer median OS (not reached; 95% CI, 24.9-33.7), than ALBI 2 (9.7 months; 95% CI, 7.0-12.3) or ALBI 3 (5.6 months; 95% CI, 0.1-12.0). ALBI outperformed the CP score for predicting 6-month OS with an AUC 0.79 of ALBI versus 0.71 for the CP score (p=0.01).</p><p><strong>Conclusion: </strong>A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.</p>\",\"PeriodicalId\":15906,\"journal\":{\"name\":\"Journal of Hepatocellular Carcinoma\",\"volume\":\"12 \",\"pages\":\"671-683\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977629/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatocellular Carcinoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/JHC.S462701\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S462701","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:Atezolizumab和bevacizumab (A+B)被推荐用于治疗不可切除的肝细胞癌(HCC)。虽然非常有效,但A+B可能导致潜在的危及生命的不良事件,包括出血。我们研究了白蛋白胆红素(ALBI)分级是否能识别出出血风险较高的患者及其对预后的影响,而不是Child-Pugh评分。方法:我们对连续治疗a +B患者的15个三级转诊中心进行了一项多中心回顾性研究。我们采用χ2检验分析ALBI分级与胃肠道出血之间的关系。采用Kaplan-Meier法估计ALBI分层的总生存期(OS),并采用ROC曲线预测6个月OS标尺的预测值。结果:纳入分析的368例患者中,ALBI 1型163例(44.3%),ALBI 2型192例(52.2%),ALBI 3型13例(3.5%)。ALBI分级与出血风险增加3倍相关(ALBI 1为3.1%,ALBI 2/3为10.2%,p=0.008)。在192名治疗前患有EGD的患者中,G2和G3静脉曲张与出血风险增加相关,而G1静脉曲张与无静脉曲张的风险相似。ALBI 1型患者的中位生存期较长(未达到;95% CI, 24.9-33.7),而ALBI 2(9.7个月;95% CI, 7.0-12.3)或ALBI 3(5.6个月;95% ci, 0.1-12.0)。ALBI在预测6个月OS方面优于CP评分,ALBI的AUC为0.79,而CP评分为0.71 (p=0.01)。结论:较高的ALBI分级与接受A+B治疗后消化道出血的风险增加相关,并且在预测较差的生存方面优于CP评分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.

Background and aims: Atezolizumab and bevacizumab (A+B) are recommended for treating unresectable hepatocellular carcinoma (HCC). Although highly effective, A+B can lead to potentially life-threatening adverse events including bleeding. We investigated whether albumin-bilirubin (ALBI) grade identifies patients with a higher risk of bleeding and its impact on prognosis than the Child-Pugh (CP) score.

Methods: We performed a multicenter retrospective study of 15 tertiary referral centers that consecutively treated patients with A+B. We analyzed the association between the ALBI grade and gastrointestinal bleeding using the χ2 test. Overall survival (OS) stratified by ALBI was estimated using the Kaplan-Meier method and the predictive value for the 6-months OS landmark with ROC curves.

Results: Of the 368 patients included in the analysis, 163 (44.3%), 192 (52.2%) and 13 (3.5%) had ALBI 1, ALBI 2, and ALBI 3, respectively. ALBI grade was associated with a 3-fold increase in bleeding risk (3.1% in ALBI 1 vs 10.2% in ALBI 2/3, p=0.008). Among 192 patients with pre-treatment EGD, G2 and G3 varices were associated with an increased risk of bleeding, whereas G1 varices had a similar risk as no varices. Patients with ALBI 1 achieved a longer median OS (not reached; 95% CI, 24.9-33.7), than ALBI 2 (9.7 months; 95% CI, 7.0-12.3) or ALBI 3 (5.6 months; 95% CI, 0.1-12.0). ALBI outperformed the CP score for predicting 6-month OS with an AUC 0.79 of ALBI versus 0.71 for the CP score (p=0.01).

Conclusion: A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信